ABIRISK
Description
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk
Accession number
dc9b062e-147a-11eb-b51f-8c8590c45a21
Project acronym
ABIRISK
Project website
Start date
2012-03-01
End date
2018-02-28
Funding
IMI1 - Call 3 (Grant number 115303)
Types
Project publications
Accession number | Title | Create date | Study | hosted at UL |
b4c2e17e-c48e-11ec-9b1d-acde48001122 | ABIRISK MS clinical and ADA data | 2016-04-01 | ABI-MS | No |
b4c2e962-c48e-11ec-9b1d-acde48001122 | ABIRISK RA clinical and ADA data | 2016-04-01 | ABI-RA | No |
b4c2ea8e-c48e-11ec-9b1d-acde48001122 | ABIRISK IBD clinical and ADA data | 2016-04-01 | ABI-IBD | No |
6bd9243b-0368-4cc9-bc92-d00ba1d40b75 | Genotyping of ABIRISK cohorts | 2016-04-01 | - | No |
Title | Primary purpose | Study type | Organism |
ABI-MS | Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment |
|
|
ABI-RA | Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients (ABI-RA) |
|
|
ABI-IBD | Anti-Biopharmaceutical Immunization : Prediction and analysis of clinical relevance to minimize the risk in Inflammatory bowel disease (IBD) |
|
|